

ForPatients

by Roche

Crohn's Disease Ulcerative Colitis Healthy Volunteers

A study to look at a new medicine called “UTTR1147A” - how safe are different doses for healthy people and patients to take – and how is this medicine processed through the body

A Safety Study of Intravenously Administered UTTR1147A in Healthy Volunteers (HVs), Participants With Ulcerative Colitis (UC), and Participants With Crohn's Disease (CD)

Trial Status
Completed

Trial Runs In
2 Countries

Trial Identifier
NCT02749630 2015-002512-32
GA29469

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This is a randomized, observer-blinded, placebo-controlled study to evaluate safety, tolerability, immunogenicity, and pharmacokinetics of repeat dosing of intravenous (IV) UTTR1147A. The study will consist of a repeat dose escalation in HVs, in participants with UC, and in participants with CD across multiple sites.

Genentech, Inc.
Sponsor

Phase 1
Phase

NCT02749630 2015-002512-32 GA29469
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥ 18 Years & ≤ 80 Years

Healthy Volunteers
Accepts Healthy Volunteers

This clinical trial was done to study a new medicine called, “UTTR1147A”, for the treatment of patients with “ulcerative colitis” and “Crohn’s disease”. This study was done to find out if UTTR1147A was safe for people and what happened to UTTR1147A inside the body. Sixty-nine people, including 38 healthy people and 31 patients took part in this study at 2 study centers in 2 countries.